Cervical Cancer

This study provides preliminary evidence that E. faecium supernatant inhibits the proliferation of cervical cancer cells and induces apoptosis, accompanied by nuclear R-loop accumulation and enhanced DNA damage signaling. HSPA5 may be involved in this process and may play a role in limiting the progression of cellular damage toward irreversible cell death in cervical cancer cells. These findings provide a new perspective for understanding the potential role of vaginal microecological factors in cervical cancer.

Cervicovaginal cytokine profiles were differentially associated with specific colposcopic findings in a site-specific manner. These findings are exploratory and hypothesis-generating, highlighting potential biological correlates of cervical changes. Further validation in larger longitudinal cohorts is required to determine whether these cross-sectional associations are reproducible and biologically meaningful.

This syngeneic orthotopic mouse model effectively replicates the metastatic cascade of cervical cancer. Its ability to closely mimic the tumor microenvironment makes this model a valuable immunocompetent orthotopic platform for investigating the metastatic mechanism and evaluating novel therapeutic strategies for cervical cancer.

In vivo, PRMT1 knockout significantly suppressed xenograft growth and reduced Ki-67 and CD31 expression. Collectively, these findings suggest that PRMT1 is an important regulator associated with cervical cancer progression and a potential candidate biomarker for prognostic assessment and therapeutic targeting, although its clinical prognostic value requires further validation.

Validation was performed using two independent Gene Expression Omnibus (GEO) datasets (GSE6791 and GSE63514)...In vitro assays demonstrated that knocking out AGPAT3 expression significantly decreased the proliferation and migration of HeLa and C-33 A cervical cancer cell line. These results suggest that AGPAT3 could be a valuable biomarker and a promising therapeutic target in cervical cancer.

P=N/A, N=500, Recruiting, University of Edinburgh | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

P2, N=49, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting

CA suppresses CC growth via concerted inhibition of EGFR/IL1B signaling and modulation of tumor immunity, warranting further pre-clinical and clinical investigation.

Non-response to the combination treatment is not characterized by immune inactivity but rather associated with sustained and coordinated increases in both activation and regulatory immune features, suggesting a shift toward systemic immune imbalance following treatment. These findings support the need for longitudinal, integrative immune monitoring strategies in future clinical trials.

High-risk patients exhibited diminished immune scores, enrichment of immunosuppressive populations including regulatory T cells and M2 macrophages, and inferior clinical outcomes. Our findings establish LDCD as a functionally important mechanism in cervical cancer at single-cell resolution and demonstrate the translational utility of integrating scRNA-seq with machine learning for the discovery of novel prognostic biomarkers and therapeutic targets.

At 15 months following initiation of therapy, the patient remains on maintenance treatment with bevacizumab and pembrolizumab, with no evidence of disease progression to date. This case highlights the potential efficacy of immune checkpoint inhibitor-containing multimodality treatment regimens in the management of advanced cervical SCNEC.

HPV-Q and PathoDetect-HPV-14 did not meet validation criteria. This study represents the first formal validation of reduced-valency HPV assays and demonstrates that Truenat-HR-HPV-Plus provides robust clinical performance with higher specificity than 14-valent assays, supporting its potential to improve screening efficiency and reduce unnecessary referrals.